{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:04:30Z","timestamp":1790874270622,"version":"4.1.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1888,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>Genetic host factors may modify the course of the hepatitis C virus (HCV) infection. Very recently, a genome-wide scan that reported association of the IL28B locus with response to treatment in HCV infection was published. The aim of the current study was to investigate the relationship of this locus with outcome of HCV infection in a cohort constituted by a total of 731 Spanish individuals. From these, 284 were subjects with persistent infection, 69 were individuals who naturally cleared the virus, and 378 were noninfected subjects. Genotyping of the rs12979860 (C&gt;T) in the IL28B locus was performed using a TaqMan 5\u2032 allelic discrimination assay. The CC genotype was overrepresented among patients infected with viral genotypes non-1 (66.7% versus 39.1% in patients infected with viral genotype-1,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 8.5 \u00d7 10\u22125, odds ratio [OR] = 0.32, 95% confidence interval [CI] 0.17-0.60); patients with spontaneous resolution of infection (72.5% versus 45.6% of the individuals with persistent infection,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 6.2 \u00d7 10\u22125, OR = 0.32; 95%CI, 0.18-0.57); and lastly, patients with sustained response (60.2% versus 32.1% found in patients with nonsustained response,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 3.1 \u00d7 10\u22125, OR = 0.31; 95%CI, 0.17-0.56).<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>\n                                 <jats:bold>We have found different rates of viral genotype infection depending on the IL28B variant as well as an association of this locus with natural and treatment-mediated response. Hepatology 2010<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.23624","type":"journal-article","created":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T20:25:12Z","timestamp":1267475112000},"page":"33-37","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":155,"title":["Interleukin-28B Genetic Variants and Hepatitis Virus Infection by Different Viral Genotypes"],"prefix":"10.1097","volume":"52","author":[{"given":"Marco Antonio","family":"Montes-Cano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ra\u00fal","family":"Garc\u00eda-Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Abad-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Romero-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Aguilar-Reina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"N\u00fa\u00f1ez-Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Francisca","family":"Gonz\u00e1lez-Escribano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20250312","doi-asserted-by":"crossref","first-page":"383398","DOI":"10.1016\/j.cld.2005.05.003","article-title":"Natural history of hepatitis C.","volume":"9","author":"Thomas","year":"2005","journal-title":"Clin Liver Dis"},{"key":"R2-6-20250312","first-page":"12281233","article-title":"Clinical outcomes after hepatitis C infection from contaminated antiD immunoglobulin: Irish Hepatology Research Group.","volume":"340","author":"KennyWalsh","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-6-20250312","doi-asserted-by":"crossref","first-page":"634651","DOI":"10.1016\/j.jhep.2008.07.013","article-title":"Treatment predictors of a sustained virologic response in hepatitis B and C.","volume":"49","author":"Kau","year":"2008","journal-title":"J Hepatol"},{"key":"R4-6-20250312","first-page":"399401","article-title":"Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance.","volume":"46","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"R5-6-20250312","doi-asserted-by":"crossref","first-page":"11001104","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon and ribavirin therapy.","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat Genet"},{"key":"R6-6-20250312","doi-asserted-by":"crossref","first-page":"11051109","DOI":"10.1038\/ng.449","article-title":"Genomewide association of IL28B with response to pegylated interferon and ribavirin therapy for chronic hepatitis C.","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"R7-6-20250312","doi-asserted-by":"crossref","first-page":"798801","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"key":"R8-6-20250312","doi-asserted-by":"crossref","first-page":"372373","DOI":"10.1016\/0168-8278(91)90084-O","article-title":"Classification of chronic viral hepatitis: a need for reassessment.","volume":"13","author":"Scheuer","year":"1991","journal-title":"J Hepatol"},{"key":"R9-6-20250312","doi-asserted-by":"crossref","first-page":"10861097","DOI":"10.1053\/j.gastro.2006.02.015","article-title":"Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferonalfa2a plus ribavirin.","volume":"130","author":"Berg","year":"2006","journal-title":"Gastroenterology"},{"key":"R10-6-20250312","doi-asserted-by":"crossref","first-page":"600609","DOI":"10.1053\/jhep.2003.50106","article-title":"Zachoval R, el al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy.","volume":"37","author":"Berg","year":"2003","journal-title":"Hepatology"},{"key":"R11-6-20250312","doi-asserted-by":"crossref","first-page":"522527","DOI":"10.1053\/j.gastro.2005.05.008","article-title":"Peginterferonalpha2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.","volume":"129","author":"von Wagner","year":"2005","journal-title":"Gastroenterology"},{"key":"R12-6-20250312","doi-asserted-by":"crossref","first-page":"124134","DOI":"10.1056\/NEJMoa066403","article-title":"Peginterferon alfa2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.","volume":"357","author":"Shiffman","year":"2007","journal-title":"N Engl J Med"},{"key":"R13-6-20250312","doi-asserted-by":"crossref","first-page":"336345","DOI":"10.1111\/j.1440-1746.2009.05789.x","article-title":"Treatment of chronic hepatitis C in Asia: when East meets West.","volume":"24","author":"Yu","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"R14-6-20250312","doi-asserted-by":"crossref","first-page":"e6579","DOI":"10.1371\/journal.pone.0006579","article-title":"The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy.","volume":"11","author":"Pang","year":"2009","journal-title":"PLoS One"},{"key":"R15-6-20250312","doi-asserted-by":"crossref","first-page":"327334","DOI":"10.1016\/j.meegid.2004.11.001","article-title":"Adaptation, coevolution, and human susceptibility to HIV1 infection.","volume":"5","author":"Telenti","year":"2005","journal-title":"Infect Genet Evol"},{"key":"R16-6-20250312","doi-asserted-by":"crossref","first-page":"641645","DOI":"10.1038\/nature07746","article-title":"Adaptation of HIV1 to human leukocyte antigen class I.","volume":"458","author":"Kawashima","year":"2009","journal-title":"Nature"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.23624","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201007000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T11:01:17Z","timestamp":1741777277000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201007000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.23624","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}